Rhythm Pharmaceuticals

Rhythm Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
2010-02-01
Employees
226
Market Cap
-
Website
http://www.rhythmtx.com
Introduction

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also...

Open-Label Study of Setmelanotide in Hypothalamic Obesity

Phase 2
Completed
Conditions
Interventions
First Posted Date
2021-01-26
Last Posted Date
2023-09-21
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
18
Registration Number
NCT04725240
Locations
🇺🇸

Children's Minnesota, Saint Paul, Minnesota, United States

🇺🇸

Seattle Children's Research Institute, Seattle, Washington, United States

🇺🇸

Rady Children's Hospital, San Diego, California, United States

and more 2 locations

A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-04-16
Last Posted Date
2021-06-30
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
32
Registration Number
NCT04348175
Locations
🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

and more 1 locations

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

First Posted Date
2018-11-19
Last Posted Date
2023-12-01
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
52
Registration Number
NCT03746522
Locations
🇺🇸

Wr-McCr, Llc, San Diego, California, United States

🇺🇸

Columbia University Center, New York, New York, United States

🇺🇸

M3 Wake Research, Raleigh, North Carolina, United States

and more 9 locations

Long Term Extension Trial of Setmelanotide

First Posted Date
2018-08-29
Last Posted Date
2024-10-28
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
300
Registration Number
NCT03651765
Locations
🇺🇸

Obesity Institute, Geisinger Clinic, Danville, Pennsylvania, United States

🇺🇸

Wake Research, Raleigh, North Carolina, United States

🇺🇸

Wake Research TN, Chattanooga, Tennessee, United States

and more 24 locations

An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes

First Posted Date
2018-08-08
Last Posted Date
2021-06-30
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
8
Registration Number
NCT03621007
Locations
🇹🇷

Ege University School of Medicine of Pediatric Endocrinology, Bornova, Turkey

🇹🇷

Pediatric Endocrinology and Diabetes Marmara University Hospital, Istanbul, Turkey

🇹🇷

Dokuz Eylul Universitesi Tip Fakultesi, Balçova, Turkey

The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry

First Posted Date
2018-03-27
Last Posted Date
2021-05-04
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
303
Registration Number
NCT03479437
Locations
🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇨🇦

University of Alberta, Edmonton, Canada

Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

First Posted Date
2017-09-19
Last Posted Date
2023-05-23
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
15
Registration Number
NCT03287960
Locations
🇳🇱

Erasmus Medical Center, Rotterdam, Netherlands

🇩🇪

University of Ulm, Ulm, Germany

🇨🇦

Markham Stouffville Hospital, Markham, Ontario, Canada

and more 3 locations

Setmelanotide in a Single Patient With Partial Lipodystrophy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2017-08-25
Last Posted Date
2022-01-04
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
1
Registration Number
NCT03262610
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

First Posted Date
2017-01-06
Last Posted Date
2023-08-18
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
213
Registration Number
NCT03013543
Locations
🇺🇸

AXIS South Florida Clinical Trials, Hialeah, Florida, United States

🇺🇸

Synexus Clinical Research US, Inc. - Akron, Akron, Ohio, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

and more 54 locations

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

First Posted Date
2016-09-12
Last Posted Date
2023-09-21
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
15
Registration Number
NCT02896192
Locations
🇩🇪

Charité Campus Virchow-Klinikum / Institute for Experimental Pediatric Endocrinology, Berlin, Germany

🇬🇧

University of Cambridge Metabolic Research Laboratories, Cambridge, United Kingdom

🇺🇸

Honor Health Research Institute, Scottsdale, Arizona, United States

and more 4 locations
© Copyright 2024. All Rights Reserved by MedPath